Your session is about to expire
← Back to Search
miRNA Modulation
miRNA for Systemic Inflammatory Response Syndrome
N/A
Waitlist Available
Led By Frederick A Willyerd, MD
Research Sponsored by Phoenix Children's Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up duration of hospital stay, an expected average of 3 weeks
Awards & highlights
Study Summary
The goal of this study is to demonstrate the sensitivity and specificity of detecting circulating micro RNA (miRNA) biomarkers in pediatric septic patients. It will also follow expression and modulation of levels in response to therapy in comparison to current biomarkers.
Eligible Conditions
- Systemic Inflammatory Response Syndrome
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ duration of hospital stay, an expected average of 3 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~duration of hospital stay, an expected average of 3 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Risk of Mortality
Secondary outcome measures
Organ Dysfunction
Organ Failure
Patient acuity
Trial Design
1Treatment groups
Experimental Treatment
Group I: miRNAExperimental Treatment1 Intervention
Find a Location
Who is running the clinical trial?
Phoenix Children's HospitalLead Sponsor
74 Previous Clinical Trials
5,013,990 Total Patients Enrolled
Frederick A Willyerd, MDPrincipal InvestigatorPhoenix Children's Hospital
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger